Clinical Trials in the USA / NCT07908316
Recruiting
Phase 1
Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)
NCT07908316 · tracked via the Priya Life Science USA tracker
Condition(s) studied
ObesityOverweight
Investigational drug(s) / intervention(s)
Maridebart cafraglutide: Administered subcutaneously.
Study summary
The primary purpose of the study is to assess the pharmacokinetics of maridebart cafraglutode after switching from weekly GLP-1RA in participants living with overweight or obesity.
Eligibility
Inclusion Criteria:
* 18 to 70 years of age.
* Body Mass Index (BMI) ≥ 25 at screening.
* BMI ≥ 23 for Asian participants at screening.
* Stable body weight (approximately 5% or less gain or loss) during the 4-week run-in period, unless the study doctor determines otherwise.
* Stable dose of weekly GLP-1RA.
* Stable gastrointestinal (GI) tolerability.
* Contraception for females.
* Stable for 3 months if obstructive sleep apnea (OSA), hypertension, hyperlipidemia, and/or hypothyroidism.
* Willingness to follow trial procedures for the duration of the trial.
Exclusion Criteria:
* Type 1/Type 2 diabetes mellitus (DM).
* Obesity induced by other endocrine disorder (ex: Cushing's syndrome).
* History of malignancy in the last 5 tears except for nonmelanoma skin cancers, cervical, or breast ductal carcinoma in situ.
* Acute \& chronic pancreatitis within 1 year.
* Uncontrolled thyroid disease.
* Gastroparesis or gastric outlet obstruction.
* Surgery for obesity in the last 6 months.
* Heart attack within 3 months.
* History of ischemic optic neuropathy.
* Positive HIV or certain positive Hepatitis B or hepatitis C.
* Current use of compounded weekly GLP-1RA.
* Previous participation in Maridebart cafraglutide trial.
* Alcohol or drug abuse.
* Pregnancy, breastfeeding, or planning to breastfeed.
Primary outcome measure(s)
- Area Under the Plasma Concentration-time Curve Over a Dosing Interval (AUCtau) of Maridebart Cafraglutide — Up To 115 days
- Maximum Observed Plasma Concentration (Cmax) of Maridebart Cafraglutide — Up To 115 days
Trial sites (9)
| Facility | City | Region | Status |
|---|---|---|---|
| Arizona Research Center | Phoenix | Arizona | Recruiting |
| Catalina Research Institute LLC (CRI) - Montclair | Montclair | California | Recruiting |
| Fortrea Clinical Research Unit - Daytona Beach | Daytona Beach | Florida | Recruiting |
| AGA Clinical Trials | Hialeah | Florida | Recruiting |
| K2 Medical Research Orlando | Maitland | Florida | Recruiting |
| The Alliance for Multispecialty Research - Lexington | Lexington | Kentucky | Recruiting |
| Alliance for Multispecialty Research - Knoxville | Knoxville | Tennessee | Recruiting |
| Fortrea Clinical Research Unit - Dallas | Dallas | Texas | Recruiting |
| Fortrea Clinical Research Unit Inc. - Madison | Madison | Wisconsin | Recruiting |
More Amgen trials in the USA
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
Recruiting
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
Active, not recruiting
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
Active, not recruiting
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07908316 on ClinicalTrials.gov ↗ ← All trials in the USA